

References

1. "Drug". Dictionary.com Unabridged. v 1.1. Random House. 20 September 2007 .
2. "Drug Definition". Stedman's Medical Dictionary. Retrieved 2014-05-01 .
3. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM, Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H (December 2015). "Discovery and resupply of pharmacologically active plant-derived natural products: A review". *Biotechnol Adv.* **33** (8).
4. "Drug". The American Heritage Science Dictionary. Houghton Mifflin Company. Retrieved 20 September 2007 .
5. Mahoney A, Evans J (6 November 2008). "Comparing drug classification systems". *AMIA Annual Symposium Proceedings*: 1039.
6. World Health Organization (2003). Introduction to drug utilization research (PDF). Geneva: World Health Organization. p. 33.
7. Bergström, CA; Andersson, SB; Fagerberg, JH; Ragnarsson, G; Lindahl, A (16 June 2014). "Is the full potential of the biopharmaceutics classification system reached?". *European Journal of Pharmaceutical Sciences.* **57**: 224–31.
8. http://www.nt.gov.au/health/healthdev/health_promotion/bushbook/volume2/chap1/sect1.htm
9. Crocq MA (June 2003). "Alcohol, nicotine, caffeine, and mental disorders". *Dialogues ClinNeurosci.* **5** (2): 175–185.
10. "Recreational Drug". The Free Dictionary. Retrieved 16 March 2015.
11. Fox, Thomas Peter; Oliver, Govind; Ellis, Sophie Marie (2013). "The Destructive Capacity of Drug Abuse: An Overview Exploring the Harmful Potential of Drug Abuse Both to the Individual and to Society". *ISRN Addiction.* **2013** Retrieved 15 April 2015.
12. "MHRA Side Effects of Medicines." MHRA Side Effects of Medicines,
13. <http://www.epgonline.org> database of prescription pharmaceutical products including drug classifications [1]

14. Spatz I, McGee N (25 November 2013). "Specialty Pharmaceuticals". Health Policy Briefs. Health Affairs. Bethesda, Maryland. What's The Background?. Retrieved 28 August 2015.
15. "Utilizing antibiotics agents effectively will preserve present day medication". News Ghana. 21 November 2015. Retrieved 21 November 2015.
16. "Antibiotics". NHS. 5 June 2014. Retrieved 17 January 2015.
17. "Factsheet for experts". European Centre for Disease Prevention and Control. Retrieved 21 December 2014.
18. For example, metronidazole: "Metronidazole". The American Society of Health-System Pharmacists. Retrieved July 31, 2015.
19. Chemical Analysis of Antibiotic Residues in Food. (PDF). John Wiley & Sons, Inc. 2012. pp. 1–60.
20. Tan, Siang Yong; Tatsumura, Yvonne (2015-07-01). "Alexander Fleming (1881–1955): Discoverer of penicillin". Singapore Medical Journal. **56** (7): 366–367.
21. Calderon CB, Sabundayo BP (2007). Antimicrobial Classifications: Drugs for Bugs. In Schwalbe R, Steele-Moore L, Goodwin AC. Antimicrobial Susceptibility Testing Protocols. CRC Press. Taylor & Frances group.
22. Finberg RW, Moellering RC, Tally FP, et al. (November 2004). "The importance of bactericidal drugs: future directions in infectious disease". Clin. Infect.
23. Cunha BA. Antibiotic Essentials 2009. Jones & Bartlett Learning, ISBN 978-0-7637-7219-2 p. 180, for example.
24. Srivastava A, Talaue M, Liu S, Degen D, Ebright RY, Sineva E, Chakraborty A, Druzhinin SY, Chatterjee S, Mukhopadhyay J, Ebright YW, Zozula A, Shen J, Sengupta S, Niedfeldt RR, Xin C, Kaneko T, Irschik H, Jansen R, Donadio S, Connell N, Ebright RH (2011). "New target for inhibition of bacterial RNA polymerase: 'switch region'". Curr. Opin. Microbiol. **14** (5).
25. Hooper, DC. (Mar–Apr 2001). "Emerging mechanisms of fluoroquinolone resistance". Emerging Infectious Diseases. **7** (2): 337–41.
26. Bergan T.; Bayer (1988). Pharmacokinetics of fluorinated quinolones. Academic Press. pp. 119–154.

27. Bergan T; Dalhoff A; Thorsteinsson SB (1985). "A review of the pharmacokinetics and tissue penetration of ciprofloxacin": 23–36.
28. Guimarães DO, Momesso LS, Pupo MT. Antibiotics: therapeutic importance and perspectives for the discovery and development of new agents. *Quím Nova*. 2010.
29. "Ciprofloxacin-Hydrochloride". *The American Society of Health-System Pharmacists*. Retrieved 3 April 2011.
30. "Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America".
31. "www.uroweb.org" (PDF).
32. "Infective Endocarditis".
33. "Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections".
34. "Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America".
35. "International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases".
36. FDA-approved drug label
37. Friedman, J.; Polifka, J. (2000). *Teratogenic effects of drugs: a resource for clinicians (TERIS)*. Baltimore, Maryland: Johns Hopkins University Press. pp. 149–195.
38. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. (1998). "Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study". *Antimicrob Agents Chemother.* **42** (6).
39. Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, et al. (1996). "Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)". *Eur J ObstetGynecolReprod Biol.* **69** (2).
40. Shin HC, Kim JC, Chung MK, Jung YH, Kim JS, Lee MK, Amidon GL (September 2003). *"Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats"*. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* **136** (1): 95–102.

41. Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H (February 1993). "Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women". *Antimicrob. Agents Chemother.* **37** (2): 293–6.
42. Dianne Murphy (30 August 2000). "Cipro Labeling Revision Letter 08/30/2000 Supplement 008 New or Modified Indication" (PDF). U.S. Food and Drug Administration.
43. Renata Albrecht (25 March 2004). "Cipro Labeling Revision Letter 03/25/2004 Supplement 049 Patient Population Altered" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 7 September 2009.
44. Lexi-Comp (February 2009). "Ciprofloxacin". Merk. Retrieved 4 September 2009.
45. A.C. Vatopoulos; V. Kalapothaki (1997). "Bacterial Resistance to Ciprofloxacin in Greece: Results from the National Electronic Surveillance System" (PDF).
46. "Bacterial resistance prompts concern among health officials". 26 February 2009. Archived from the original on 5 March 2009.
47. M Jacobs, Worldwide Overview of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005.
48. "Update On Extra-Label Use Of Fluoroquinolones" (Press release). Center for Veterinary Medicine (CVM). 16 July 1996. Retrieved 12 August 2009.
49. "Ciprofloxacin spectrum of bacterial susceptibility and Resistance" (PDF). Retrieved 4 May 2012.
50. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS (March 2005). "Fluoroquinolone prescribing in the United States: 1995 to 2002". *Am. J. Med.* **118** (3): 259–68.
51. Brown KA, Khanafer N, Daneman N, Fisman DN (May 2013). "Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection". *Antimicrob. Agents Chemother.* **57** (5): 2326–32.
52. Falagas ME, Matthaiou DK, Vardakas KZ (December 2006). "Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials". *Mayo Clin. Proc.* **81** (12): 1553–66.
53. Knottnerus BJ, Grigoryan L, Geerlings SE, et al. (December 2012). "Comparative effectiveness of antibiotics for uncomplicated urinary tract

infections: network meta-analysis of randomized trials". FamPract. 29 (6): 659–70.

54. FDA-approved package insert

55. Belal F, Al-Majed AA, Al-Obaid AM. Methods of analysis of 4-quinolone antibacterials.

56. *Metha, Akul (14 May 2012). "Limitations and Deviations of Beer-Lambert Law". PharmaXChange.info.*

57. Gerber, F.; Krummen, M.; Potgeter, H.; Roth, A.; Siffrin, C.; Spoendlin, C. (2004). "Practical aspects of fast reversed-phase high-performance liquid chromatography using 3µm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice". *Journal of Chromatography A*. **1036** (2): 127–133.

58. Chung Ch, Ch. Herman, L. Lee Y,C and Zhang, X. (2004) Analytical method validation and instrument performance verification, John Wiley & Sons, Inc., Hoboken, Publication, NewJerse

59. FDA. (2001) Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).

60. BP (British Pharmacopoeia). (2009) The Pharmaceutical Press, Her Majesty's Stationery Office, London, Vol. I and II.

61. World Health Organization (WHO). (2006) Supplementary guidelines on good manufacturing practices: validation; WHO Technical Report Series, No. 937, 2006

62. Swartz M. (2009) Developing and Validating Dissolution Procedures for Improved Product Quality, synomics pharm, www.synomicspharma.com

63. International Conference on Harmonization (ICH). (2005) Validation of Analytical Procedures, Text and Methodology, Q2 (R1).

64. USP (The United States Pharmacopoeia). (2008) USP31/NF26, Rockville, Vol.1, MD, USA.